An analysis of the diffusion of new antidepressants: Variety, quality, and marketing efforts

Journal of Mental Health Policy and Economics

Volumn 5, Issue 1, 2002, Pages 3-19

  Berndt, Ernst R ^a   Bhattacharjya, Ashoke ^b   Mishol, David N ^c   Arcelus, Almudena ^c   Lasky, Thomas ^b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c ANALYSIS GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; FLUOXETINE; FLUVOXAMINE MALEATE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEW DRUG; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TETRACYCLIC ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANALYTICAL PARAMETERS; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DIARRHEA; DRUG APPROVAL; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG OVERDOSE; DRUG QUALITY; FEMALE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEALTH ECONOMICS; HUMAN; MALE; MULTIVARIATE ANALYSIS; PHYSICIAN ATTITUDE; QUANTITATIVE ANALYSIS; REGRESSION ANALYSIS; SEXUAL DYSFUNCTION; SIMULATION; SLEEP DISORDER; UNITED STATES; XEROSTOMIA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; DIFFUSION OF INNOVATION; DRUG APPROVAL; DRUG COSTS; DRUG UTILIZATION; DRUGS, INVESTIGATIONAL; FORECASTING; HUMANS; MARKETING; QUALITY CONTROL; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0036523761     PISSN: 10914358     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Anderson SP, De Palma A, Thisse JF. Discrete Choice Theory of Product Differentiation. Cambridge, MA: The MIT Press, 1992.
2. Weitzman ML. On diversity. Q J Econ 1992; 74 (2): 363-405.
3. Dixit AK, Stiglitz JE. Monopolistic competition and optimum product diversity. Am Econ Rev 1977; 67 (3) (June): 297-308.
4. Berry ST. Estimating discrete-choice models of product differentiation. Rand J Econ 1994; 25(2) (Summer): 242-262.
5. Berry ST, Pakes A. Some applications and limitations of recent advances in empirical industrial organization: merger analysis, Am Econ Rev 1993; 83 (2) (May): 247-252.
6. Berry ST, Levinsohn J, Pakes A. Automobile prices in market equilibrium. Econometrica 1993; 63 (4) (July): 841-890.
7. Schmalensee RL. Econometric diagnosis of competitive localization. International Journal of Industrial Organization 1985; 3 (March): 57-70.
8. Stavins J. Model entry and exit in a differentiated product industry: The personal computer market. Rev Econ Stat 1995; 77 (3): 571-584.
9. Arrow KJ. Uncertainty and the welfare economics of medical care. Am Econ Rev 1963; 53: 941-969.
10. Nelson P. Information and consumer behavior. J Polit Econ 1970; 78 (2) (March/April): 311-329.
11. Nelson P. Advertising as information. J Polit Econ 1974; 82 (4) (July/August): 729-754.
12. Stigler G. The economics of information. J Polit Econ 1961; 69 (3) (June): 213-225.
13. RB, Haulman CA, Moody CE. Quality, price, advertising and published quality ratings. J Consum Res 1983; 9 (March): 347-356.
14. Phillips LW, Chang DR, Buzzell RD. Product quality, cost position and business performance: A test of some key hypotheses. J Mark 1983; 47 (1): 26-43.
15. Grossman GM, Shapiro C. Informative advertising with differentiated products. Rev Econ Stud 1984; 51: 63-81.
16. Milgrom P, Roberts J. Price and advertising signals of product quality. J Polit Econ 1986; 94: 796-821.
17. Carlton DW, Perloff JM. Modern Industrial Organization, Second Edition, New York: Harper Collins College Publishers, 1984, Ch. 15.
18. Azoulay P. Do pharmaceutical sales respond to scientific evidence? Unpublished manuscript, Columbia University Graduate School of Business, New York, 2002. Forthcoming, Journal of Economics and Management Strategy.
19. Bond RS, Lean DF. Sales, promotion, and product differentiation in two prescription drug markets. Economic Report, Washington DC, Federal Trade Commission, 1977.
20. Berndt ER, Bui LT, Reiley DH, Urban GL. Information, marketing, and pricing in the US antiulcer drug market. Am Econ Rev 1995; 85 (2) (May): 100-105.
21. Berndt ER, Bui LT, Reiley DH, Urban GL. The roles of marketing, product quality, and price competition in the growth and composition of the US antiulcer drug industry. In Timothy M. Bresnahan and Robert J. Gordon (eds.) The Economics of New Products. Chicago: University of Chicago Press, 1997: 277-322.
22. Grabowski H, Vernon J. Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 Drug Act. Journal of Law and Economics 1992; 35: 331-350.
23. Bagwell K. Informational product differentiation as a barrier to entry. International Journal of Industrial Organization 1990; 8: 207-223.
24. Carpenter GS, Nakamoto K. Consumer preference formation and pioneering advantage. J Mark Res 1989; 26 (8): 285-298.
25. Robinson WT, Kalyanaram G, Urban GL. First mover advantages for pioneering new products: A survey of empirical evidence. Review of Industrial Organization 1994; 9 (1):1-23.
26. Urban GL, Carter T, Gaskin S, Mucha Z. Market share rewards to pioneering brands: An empirical analysis and strategic implications. Manage Sci 1986; 32 (6) (June): 537-562.
27. Hurwitz MA, Caves RE. Persuasion or information? Promotion and the shares of brand name and generic pharmaceuticals. Journal of Law and Economics 1988; 31 (October): 299-320.
28. Leffler KB. Persuasion or information? The economics of prescription drug advertising. Journal of Law and Economics 1981; 24 (1): 45-74.
29. Katon, WB, Sullivan MD. Depression and chronic medical illness. J Clin Psychiatry 1990; 5 (6): 3-11.
30. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey I: Lifetime prevalence, chronicity and recurrence. J Affec Disord 1993; 29: 85-96.
31. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshlerman S, Wittchen H-U, Kendler KS. Lifetime and twelve-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 1: 8-19.
32. Keller MB, Kocsis JH, Thase ME, Gelenberg AJ, Rush AJ, Koran LM, Schatzberg AF, Russell JM, Hirschfeld RMA, Klein DN, McCullough JP, Fawcett JA, Kornstein SM, LaVange L, Harrison WM. Maintenance phase efficacy of sertraline for chronic depression: A randomized controlled trial. J Am Med Assoc 1998; 280 (19): 1665-1672.
33. Kupfer, DJ. Long-term treatment of depression. J Clin Psychiatry 1991; 52 (5) supplement: 28-34.
34. Kupfer DJ, Frank E, Perel JM. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992; 49: 769-773.
35. National Institutes of Mental Health. A consensus development conference statement, mood disorders: pharmacological prevention of recurrence. Am J Psychiatry 1985: 142: 469-476.
36. Thase ME. Relapse and recurrence in unipolar major depression: Short-term and long-term approaches. J Clin Psychiatry 1990; 51 (6) supplement: 51-57.
37. Thase ME, Howland R. Biological processes in depression: An updated review and integration. In E. Beckham and E.E. Leber (eds.) Handbook of Depression. Second Edition, New York: Guilford Publications, 1995: 213-279.
38. Eisenberg, L. Treating depression and anxiety in primary care: Closing the gap between knowledge and practice. N Engl J Med 1992; 326: 1080-1084.
39. Franko KJ, Jamburrino M, Campbell N, Evans C, Zrull J, Bronson D. The added costs of depression to medical care. Pharmacoeconomics 1995; 7 (4): 284-291.
40. Freeling P, Rao BM, Paykel ES, Sireling LI, Burton RH. Unrecognized depression in general practice. Br Med J 1985; 290: 1880-1883.
41. Hirschfeld RMA, Keller MB, Panico S, Arons BS, Barlow D, Davidoff F, Endicott J, Froom J, Goldstein M, Gorman JM, Marek RG, Maurer TA, Meyer R, Phillips K, Ross J, Schwenk TL, Sharfstein SS, Thase ME, Wyatt RJ. The national depressive and manic-depressive association consensus statement on the undertreatment of depression. J Am Med Assoc 1997; 277 (4): 333-340.
42. Katon WB, von Korff M, Lin E, Bush T, Ormel J. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992; 30 (1): 67-76.
43. Depression Guideline Panel. Depression in Primary Care, Volume 2: Treatment of Major Depression, Clinical Practice Guideline, no. 5. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, AHCPR Publication 93-0551, April 1993.
44. Nemeroff CB. Evolutionary trends in the pharmacotherapeutic management of depression. J Clin Psychiatry 1994; 55: 3-15.
45. Regier DA, Hirschfeld RMA, Goodwin FK, Burke JD, Lazar JB, Judd LL. The NIMH Depression Awareness, Recognition, and Treatment Program: Structure, aims, and scientific basis. Am J Psychiatry 1988: 145: 1351-1357.
46. Baldessarini RJ. Current status of antidepressants: Clinical pharmacology and therapy. J Clin Psychiatry 1989; 50: 117-126.
47. Berndt ER, Cockburn IM, Griliches Z. Pharmaceutical innovations and market dynamics: tracking effects on price indexes for antidepressant drugs. Brookings Pap Econ Act, Microeconomics 1996: 133-188.
48. Johnson RE, McFarland BH, Nichols GA. Changing patterns of antidepressant use and costs in a health maintenance organization. Pharmacoeconomics 1997; 22 (3): 274-286.
49. Anderson IM. SSRIs versus tricyclic antidepressants in depressed patients: A meta analysis of efficacy and tolerability. Depress Anxiety 1998; 7, Supplement 1: 11-17.
50. Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affec Disord 2000; 59: 119-126.
51. Kroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R, Stang P, Zhou X-H, Hays R, Weinberger M. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. J Am Med Assoc 2001; 286 (23): 2947-2955.
52. Garber AM. Cost and control of antibiotic resistance. Cambridge MA: Harvard University, Department of Economics, unpublished Ph.D. dissertation, 1982.
53. Ellison SF, Hellerstein JK. The economics of antibiotics. In Measuring the Prices of Medical Treatments, Jack E. Triplett (ed.), Washington, DC: The Brookings Institution, 1999: 118-143.
54. Schmalensee RL. Product differentiation advantages of pioneering brands. Am Econ Rev 1982; 72 (3): 349-365.
55. Bhattacharjya AS. Product experimentation and learning under reswitching. Econometric Society meetings, unpublished paper, 1994.
56. Bailey MN. Comments on Berndt, Cockburn and Griliches. Brookings Pap Econ Act, Microeconomics 1996: 194-199.
57. Okun AM. Prices and Quantities: A Macroeconomic Analysis. Washington DC: The Brookings Institution, 1981.
58. Jovanovic B. Job matching and the theory of turnover. J Polit Econ 1979; 87 (5): 972-990.
59. Miller RA. Job matching and occupational choice. J Polit Econ 1984; 92 (6): 1086-1120.
60. Eckstein Z, Wolpin K. On the estimation of labour force participation, job search, and job matching models using panel data. In Advances in the Theory and Measurement of Unemployment, Yoram Weiss and Gideon Fishelson (eds.) New York: McMillan, 1987.
61. Gatignon H, Weitz B, Bansal P. Brand introduction strategies and competitive environments. J Mark Res 1990; 27 (11): 390-401
62. King CK III. Marketing, product differentiation and competition in the market for antiulcer drugs. Harvard Business School Working Paper No. 01-014, 2000.
63. Bergmann D, Valimaki J. Market diffusion with two-sided learning. RAND J Econ 1997; 28 (4) (Winter): 773-795.
64. Berndt ER, Pindyck RS, Azoulay P. Network effects and diffusion in pharmaceutical markets: Anti-ulcer drugs. MIT Sloan School of Management, unpublished manuscript, 24 February 1999.